KBI Biopharma Unveils KBI PUREplatform™, a Game-Changing Microbial Expression Offering to Redefine Biopharmaceutical Manufacturing
KBI Biopharma, Inc. (KBI), a JSR Life Sciences company, today announced the launch of KBI PUREplatform™, a premium microbial cell line development (CLD) platform that features unmatched efficiencies in a microbial expression system for biopharmaceutical production. A culmination of decades of KBI’s therapeutic protein development and industry expertise, the platform addresses known industry challenges such as low titers, poor product quality, and capacity constraints, empowering customers to significantly improve processes to bring products to market cheaper and easier.
Engineered for commercial use, the platform features KBI’s PUREcoli™ high-producing E. coli cell line, expertly paired with PUREplasmids™ and PUREmedia™ available in 8, 24, 48, and 96 screening packages – with future strains and screening packages under development. A robust, efficient platform, predictive development, and scalable high throughput workflows quickly feed upstream process development and late-stage manufacturing. Our protein expression is individually tailored to each customer’s requirements.
“With the introduction of the KBI PUREplatform, we're poised to extend the boundaries of expression system and process synergy, underscoring KBI’s commitment to innovation and customer-centric solutions across all business segments,” said Sigma Mostafa, KBI Biopharma’s Chief Scientific Officer. “We always strive to stay a step ahead with significant production advancements. With this platform, we’re redefining the microbial expression landscape and raising the floor of efficiencies to create new market opportunities for scalable expression systems.”
The advanced system and modified strain outperform common K-12 or B strain E. coli by growing 50% faster, reducing production time by nearly half a day per batch. PUREcoli stands out for its safety and efficiency, with 100 fewer virulence or immunogenicity related genes, eliminating the need for antibiotics in plasmid maintenance.
“The results our development team is seeing with PUREplatform are paving the way for our partners to realize microbial drug substance at a fraction of the scales previously needed, and we hope to see this translate into more efficient cost of goods for at-scale manufacturing,” said J.D. Mowery, Chief Executive Officer of KBI Biopharma.
About KBI Biopharma, Inc.
KBI Biopharma, Inc., a JSR Life Sciences company, together with its affiliates, is a global contract development and manufacturing organization (CDMO) providing fully integrated, accelerated drug development and biologics manufacturing services and expertise to life science companies. As a global leader in mammalian cell line development, with best-in-class modular technology and highly specialized solutions, KBI enables the life sciences industry to rapidly discover, develop and commercialize innovative medicines and vaccines. With each of its 500+ client partners, KBI works closely to personalize and rapidly accelerate drug development programs.
Global partners are utilizing KBI’s technologies to advance more than 160 drug candidates in preclinical and clinical development and the manufacture of ten commercial products. Built upon a foundation of world-class analytics capabilities and extensive scientific and technical expertise, KBI delivers robust process development and clinical and commercial cGMP manufacturing services for mammalian, microbial, and cell therapy programs. Recognized for quality manufacturing, KBI helps partners advance drug candidates to the market. KBI serves its global partners with eight locations in Europe and the USA. More information is available at www.kbibiopharma.com
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230605005217/en/
Contact information
KBI Biopharma, Inc. Company Inquiries
Leah Farmer
KBI Biopharma, Inc.
lfarmer@kbibiopharma.com
KBI Biopharma, Inc. Media Inquiries
Blair Ciecko
CG Life
bciecko@cglife.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Spatial Releases 2025 1.0.1 with Enhancements for CAD Translation, Model Simplification, and Mesh Preparation for Manufacturing and Simulation2.5.2025 17:47:00 EEST | Press release
Spatial Corp., the leading software development toolkit provider for design, manufacturing and engineering solutions and a subsidiary of Dassault Systèmes, announces the 2025 1.0.1 release and updates across several product lines, reaffirming its commitment to providing innovative solutions for its customers in domains ranging from CAD to simulation, manufacturing, and beyond. The 2025 1.0.1 release delivers expanded functionality designed to streamline manufacturing and simulation workflows. Key highlights include a new custom feature detection API in ACIS for more efficient model simplification, expanded CAD format support—including STEP AP242 PMI writing—and continued enhancements to hidden-body removal. With this release, Spatial reduces manual tasks, increases fidelity in geometry translation, and strengthens its toolset for automated design-to-manufacture and design-to-simulation pipelines. 3D ACIS Modeler Custom Feature Detection (Beta): Model simplification often requires manua
Decent Cybersecurity Joins the Council of Slovak Exporters to Strengthen European Cybersecurity Exports2.5.2025 16:51:00 EEST | Press release
Decent Cybersecurity, a leading European provider of post-quantum security solutions, announces its membership in the Council of Slovak Exporters (CSE), reinforcing its commitment to expanding advanced cybersecurity exports across global markets. This strategic partnership combines Decent Cybersecurity's expertise in critical infrastructure protection with CSE's established export promotion platform. As a company holding national, EU, and NATO "Secret" level security clearances, Decent Cybersecurity brings specialized knowledge in post-quantum security, blockchain technology, and space traffic management solutions to the Council's network. "Joining the Council of Slovak Exporters represents a significant opportunity to strengthen Slovakia's position in the global cybersecurity market," said Matej Michalko, Founder and CEO of Decent Cybersecurity and a long-term expert on post-quantum cryptography and blockchain. "As cyber threats continue to evolve, our advanced solutions are increasin
Saudi Arabia Hosts EDGEx 2025, Pushing the Boundaries of Education2.5.2025 16:29:00 EEST | Press release
Saudi Arabia has taken another step forward in its educational reform journey with the successful conclusion of the International Education Exhibition (EDGEx), held from April 13–16, 2025. Organized by the Ministry of Education, the event convened education leaders, technology developers, and policymakers from around the world under the theme “Beyond Readiness.” This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250502190798/en/ Saudi Arabia Hosts EDGEx 2025, Pushing the Boundaries of Education (Photo: AETOSWire) Over four days, EDGEx welcomed more than 20,000 local and international visitors, including government representatives, senior educators, academics, business leaders, and professionals in the field. The exhibition served as a platform for dialogue, knowledge exchange, and cross-sector collaboration—bringing together institutions, companies, and decision-makers to explore how education and training can evolve in a rapidl
IFF Announces Tender Offers for Certain Outstanding Series of Notes2.5.2025 16:10:00 EEST | Press release
IFF (NYSE: IFF) announced today the commencement of tender offers to purchase for cash certain of its outstanding series of notes listed in the tables below (collectively, the “Notes”) for an aggregate purchase price, excluding accrued and unpaid interest, of up to $1.8 billion. Pool 1 Tender Offers Pool 1 Maximum Amount: $1.0 billion(1(a)) Title of Security CUSIP/ISIN Principal Amount Outstanding(in millions) Acceptance Priority Level(2) Series Tender Cap(3) U.S. Treasury Reference Security Bloomberg Reference Page Fixed Spread(4) Early Tender Payment (4)(5) 1.230% Senior Notes due 2025 459506AN1 U45950AE9 $1,000 1 $500 million 5.000% UST due 9/30/25 FIT3 + 0 bps $30 1.832% Senior Notes due 2027 459506AP6 U45950AF6 $1,200 2 $300 million 3.750% UST due 4/30/27 FIT1 + 75 bps $30 2.300% Senior Notes due 2030 459506AQ4 U45950AG4 $1,500 3 N/A 3.875% UST due 4/30/30 FIT1 + 110 bps $30 4.450% Senior Notes due 2028 459506AK7 US459506AK78 $400 4 N/A 3.750% UST due 4/15/28 FIT1 + 95 bps $30 Poo
Heidrick & Struggles Appoints a New Managing Partner for Their CEO & Board Practice in Europe and Africa2.5.2025 11:27:00 EEST | Press release
Heidrick & Struggles (Nasdaq: HSII), a premier provider of executive search, global leadership advisory and on-demand talent solutions, has appointed Kati Najipoor-Smith as Regional Co-Managing Partner, CEO & Board Practice, for Europe and Africa. Based at the Firm’s office in Frankfurt, Germany, Kati brings decades of global executive search and consulting experience to the Heidrick & Struggles team to support boards and CEOs in navigating complex leadership challenges. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250501269229/en/ Kati Najipoor-Smith has been appointed Heidrick & Struggles' Regional Co-Managing Partner, CEO & Board Practice, for Europe and Africa Kati began her executive search career at Egon Zehnder in 1999, where she led Global Automotive and later the Global CEO Practice over several years. She advises chairs and CEOs of publicly traded, family-owned, and private-equity-backed companies across sectors
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom